# Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma

> **NCT01849263** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 41 (actual)

## Conditions studied

- Grade 3a Follicular Lymphoma
- Recurrent Grade 1 Follicular Lymphoma
- Recurrent Grade 2 Follicular Lymphoma
- Recurrent Grade 3 Follicular Lymphoma
- Refractory Follicular Lymphoma

## Interventions

- **DRUG:** Ibrutinib
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT01849263
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2013-04-02
- **Primary completion:** 2016-06-03
- **Final completion:** 2027-03-19
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01849263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01849263, "Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01849263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*